From wiki-pain
Revision as of 04:28, 22 September 2012 by Daniel (Talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Context Info
Confidence 0.42
First Reported 2005
Last Reported 2011
Negated 0
Speculated 0
Reported most in Body
Documents 5
Total Number 5
Disease Relevance 1.70
Pain Relevance 0.56

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (Edn1) extracellular region (Edn1) cell-cell signaling (Edn1)
cytoplasm (Edn1)
Anatomy Link Frequency
endothelial cells 2
smooth muscle 2
endothelium 2
lung 2
Edn1 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
medulla 19 79.44 Quite High
agonist 22 77.12 Quite High
Calcitonin gene-related peptide 39 75.52 Quite High
qutenza 14 75.36 Quite High
Potency 3 70.96 Quite High
antagonist 50 56.08 Quite High
local anesthetic 7 50.00 Quite Low
Neurotransmitter 4 28.28 Quite Low
chemokine 3 19.72 Low Low
adenocard 7 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Diabetes Mellitus 132 96.76 Very High Very High Very High
Increased Venous Pressure Under Development 8 95.16 Very High Very High Very High
Renal Disease 8 90.32 High High
Myocardial Infarction 21 89.96 High High
Natriuresis 8 85.12 High High
Stress 5 72.20 Quite High
Pressure And Volume Under Development 9 65.52 Quite High
Acute Decompensated Heart Failure (ADHF) 23 63.20 Quite High
Syndrome 48 57.20 Quite High
Apoptosis 3 52.56 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Binding of Rh-ET-1 (16 nM) to smooth muscle (Fig. 6D) was reduced by BQ788 (1 µM; Fig. 6E) and was prevented by presence of either ET-1 (16 nM) or of both BQ788 (1 µM) and BQ123 (1 µM)[2] indicating selective binding to ETA- and ETB-receptors.
Negative_regulation (prevented) of Localization (presence) of ET-1 in smooth muscle
1) Confidence 0.42 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2879375 Disease Relevance 0 Pain Relevance 0.45
CONCLUSION: Bupivacaine and ropivacaine attenuated N-formyl-L-leucine-methionyl-L-phenylalanine-induced PAP, reduced lung edema, and diminished ET-1 release.
Negative_regulation (diminished) of Localization (release) of ET-1 in lung
2) Confidence 0.41 Published 2009 Journal Anesth. Analg. Section Body Doc Link 19690261 Disease Relevance 0 Pain Relevance 0
Although the mechanisms of ET-1 elevation during diabetes are relatively unknown, several research groups speculated that this increase could be due to an abnormal production by the affected endothelium [31] or lack of suppression of ET-1 release secondary to attenuated endothelium-derived relaxing factor production [32].
Negative_regulation (suppression) of Localization (release) of ET-1 in endothelium associated with diabetes mellitus
3) Confidence 0.37 Published 2005 Journal Cardiovasc Diabetol Section Body Doc Link PMC555576 Disease Relevance 0.76 Pain Relevance 0.08
RESULTS: Pretreatment with LAs significantly reduced the FMLP-induced PAP increase (treatment group v sham group: 0.5 to 5 mm Hg v 8 mm Hg; P < .05) and the release of endothelin-1 (2.4 v 5 fmol/mL).
Negative_regulation (reduced) of Localization (release) of endothelin-1
4) Confidence 0.17 Published 2006 Journal Reg Anesth Pain Med Section Body Doc Link 16701192 Disease Relevance 0 Pain Relevance 0
Whereas AII stimulates the release of ET 1, NO inhibits ET 1 release from endothelial cells.
Negative_regulation (inhibits) of Localization (release) of ET 1 in endothelial cells
5) Confidence 0.04 Published 2011 Journal International Journal of Nephrology Section Body Doc Link PMC2989717 Disease Relevance 0.94 Pain Relevance 0.03

General Comments

This test has worked.

Personal tools